439 related articles for article (PubMed ID: 23652609)
1. Results of pretransplant treatment of hepatorenal syndrome with terlipressin.
Solà E; Cárdenas A; Ginès P
Curr Opin Organ Transplant; 2013 Jun; 18(3):265-70. PubMed ID: 23652609
[TBL] [Abstract][Full Text] [Related]
2. Terlipressin in hepatorenal syndrome: Evidence for present indications.
Rajekar H; Chawla Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
[TBL] [Abstract][Full Text] [Related]
3. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.
Boyer TD; Sanyal AJ; Garcia-Tsao G; Regenstein F; Rossaro L; Appenrodt B; Gülberg V; Sigal S; Bexon AS; Teuber P;
Liver Transpl; 2011 Nov; 17(11):1328-32. PubMed ID: 21837734
[TBL] [Abstract][Full Text] [Related]
4. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
Ganne-Carrié N; Hadengue A; Mathurin P; Durand F; Erlinger S; Benhamou JP
Dig Dis Sci; 1996 Jun; 41(6):1054-6. PubMed ID: 8654133
[TBL] [Abstract][Full Text] [Related]
5. Hepatorenal syndrome: the clinical impact of vasoactive therapy.
Colle I; Laterre PF
Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):173-188. PubMed ID: 29258378
[TBL] [Abstract][Full Text] [Related]
6. Hepatorenal syndrome and novel advances in its management.
Fabrizi F; Aghemo A; Messa P
Kidney Blood Press Res; 2013; 37(6):588-601. PubMed ID: 24356549
[TBL] [Abstract][Full Text] [Related]
7. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
8. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes.
Rodriguez E; Henrique Pereira G; Solà E; Elia C; Barreto R; Pose E; Colmenero J; Fernandez J; Navasa M; Arroyo V; Ginès P
Liver Transpl; 2015 Nov; 21(11):1347-54. PubMed ID: 26178066
[TBL] [Abstract][Full Text] [Related]
9. Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
Piano S; Gambino C; Vettore E; Calvino V; Tonon M; Boccagni P; Gringeri E; Germani G; Burra P; Cillo U; Angeli P
Hepatology; 2021 May; 73(5):1909-1919. PubMed ID: 32870499
[TBL] [Abstract][Full Text] [Related]
10. Review article: pharmacological treatment of hepatorenal syndrome.
Ginès P; Torre A; Terra C; Guevara M
Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():57-62; discussion 63-4. PubMed ID: 15335404
[TBL] [Abstract][Full Text] [Related]
11. Hepatorenal syndrome in patients with cirrhosis.
Moreau R
J Gastroenterol Hepatol; 2002 Jul; 17(7):739-47. PubMed ID: 12121502
[TBL] [Abstract][Full Text] [Related]
12. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in our understanding of hepatorenal syndrome.
Wong F
Nat Rev Gastroenterol Hepatol; 2012 May; 9(7):382-91. PubMed ID: 22614754
[TBL] [Abstract][Full Text] [Related]
14. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.
Restuccia T; Ortega R; Guevara M; Ginès P; Alessandria C; Ozdogan O; Navasa M; Rimola A; Garcia-Valdecasas JC; Arroyo V; Rodés J
J Hepatol; 2004 Jan; 40(1):140-6. PubMed ID: 14672625
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the management of hepato-renal syndrome (HRS).
Fabrizi F; Martin P; Messa P
Acta Clin Belg; 2007; 62 Suppl 2():393-6. PubMed ID: 18284007
[TBL] [Abstract][Full Text] [Related]
16. Hepatorenal syndrome.
Angeli P; Morando F; Cavallin M; Piano S
Contrib Nephrol; 2011; 174():46-55. PubMed ID: 21921608
[TBL] [Abstract][Full Text] [Related]
17. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
[TBL] [Abstract][Full Text] [Related]
18. Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin.
Weinberg EM; Wong F; Vargas HE; Curry MP; Jamil K; Pappas SC; Sharma P; Reddy KR
Liver Transpl; 2024 Apr; 30(4):347-355. PubMed ID: 37801553
[TBL] [Abstract][Full Text] [Related]
19. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
Piano S; Morando F; Fasolato S; Cavallin M; Boscato N; Boccagni P; Zanus G; Cillo U; Gatta A; Angeli P
J Hepatol; 2011 Aug; 55(2):491-6. PubMed ID: 21334405
[TBL] [Abstract][Full Text] [Related]
20. Terlipressin in the management of adults with hepatorenal syndrome-acute kidney injury (HRS-AKI).
Kulkarni AV; Lee J; Reddy KR
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1067-1079. PubMed ID: 37856367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
